Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

October 24, 2012

Wellesley, Mass. – According to a new technical market research report, NUCLEIC ACID APTAMERS FOR DIAGNOSTICS AND THERAPEUTICS: GLOBAL MARKETS (BIO071B), from BCC Research (www.bccresearch.com), the global aptamer market was valued at $40 million in 2011 and should reach nearly $99 million in 2012. Total market value is expected to reach nearly $3.7 billion in 2017 with a five-year compound annual growth rate (CAGR) of 106.3%.

The market for nucleic acid aptamers can be broken down between aptamer therapeutics and aptamer-based in-vitro diagnostics.

The therapeutics segment of this market is expected to have a value of $13 million in 2012 and $1.7 billion in 2017, a CAGR of 165%.

The aptamer-based in-vitro diagnostics segment should total $86 million in 2012 and $2 billion in 2017, a CAGR of 87.6%.

U.S. sales for Macugen, the first FDA-approved aptamer drug, were $14.25 million in 2011.

To date, there has been only one FDA-approved, commercialized aptamer therapeutic (Macugen) available in the United States or elsewhere. Despite this fact, we believe it is quite reasonable to expect significant new market entrants in the near future. The exact timeline for the introduction of these new products is difficult to predict but is conservatively reflected here based on a significant number of companies involved in the aptamer space and compounds in various stages of clinical and preclinical trials.

This report will help its readers:

• Determine  the specific applications and global market demand for nucleic acid  aptamers for therapeutic and diagnostic purposes
• Identify  emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
• Receive quantitative market analysis as well as an overview of the intellectual property landscape
• Highlight the roles played by key players in the market.

This report will be valuable to many industry participants, including the following:

• Biotechnology industry specialists
• Therapeutic antibodies developers
• In-vitro diagnostics developers
• Academic and research institutions
• End users and distributors
• Financial institutions.

Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets( BIO071B )
Publish Date: Oct 2012    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.